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A B S T R A C T
Background: Previous reports have suggested the importance of delayed arterial healing and the
development of neoatherosclerosis as major contributors to stent thrombosis and delayed restenosis.
The difference of in vivo assessment of long-term vessel healing between ﬁrst-generation drug-eluting
stents and current generation everolimus-eluting stents (EESs) is limited. The aim of this study was to
evaluate long-term arterial healing in EES in comparison with the ﬁrst generation sirolimus-eluting
stents (SES).
Methods: We evaluated 31 EES (23 patients) and 8 SES (7 patients) by serial optical coherence
tomography at 12 months (mid-phase) and 24 months (late-phase) after stenting and evaluated the
change in neointimal thickness (NIT), the percentages of uncovered struts, peri-strut low intensity area
(PLIA; region around stent struts homogenously lower-intensity appearance than surrounding tissue),
and thrombus.
Results: Although the average NIT showed no signiﬁcant changes from the mid- to the late-phase follow-
up in both EES and SES groups, the change in NIT and minimum lumen area was signiﬁcantly larger in SES
than EES (5.2  29.4 vs. 37.2  48.9; p = 0.02, 0.06  0.36 vs. 0.45  0.74; p = 0.04, respectively). The
incidence of uncovered struts and struts with PLIA of EES was lower than those of SES, at both phases. Stents
with in-stent thrombus of EES tended to be lower than that of SES at both phase follow-ups.
Conclusion: Although both SES and EES showed progressive luminal narrowing from the mid- to the late-
phase follow-up, the extent of delayed lumen narrowing and delayed neointimal proliferation was
signiﬁcantly less in the second generation EES than the ﬁrst generation SES. EESs seem to offer sustained
stability in efﬁcacy, without sacriﬁcing safety, up to 2 years after implantation.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Late stent thrombosis [1] and delayed restenosis [2] have
become long-term concerns after drug-eluting stent (DES)
treatment. Although these are multifactorial, previous investiga-
tors have implicated delayed arterial healing and the development* Corresponding author at: Kobe University Graduate School of Medicine,
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mechanisms of these phenomena [3].
Optical coherence tomography (OCT) is a high-resolution
intravascular imaging modality and some of these OCT ﬁndings
(e.g. uncovered struts, malapposed struts, and thrombus forma-
tion) have been demonstrated to be associated with stent
thrombosis and target lesion revascularization [4,5].
Although several studies have used sequential OCT examina-
tion to investigate the time course of arterial healing after ﬁrst-
generation DES implantation [6,7], there is little information about
the difference in serial changes in vessel reactions to current
generation everolimus-eluting stents (EESs) [8]. reserved.
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course of arterial healing after EES and sirolimus-eluting stents
(SES) implantation, evaluated by matched serial OCT examina-
tions, in patients with coronary artery disease.
Methods
Study population
We identiﬁed 225 consecutive patients treated with SES
(Cypher; Cordis Corp., Miami Lakes, FL, USA) between October
2004 (when SES launched in Japan) and May 2010, and 130
patients with EES (XIENCE V, Abbott Vascular, Santa Clara, CA, USA;
PROMUS, Boston Scientiﬁc, Natick, MA, USA) between January
2010 (when EES launched in Japan) and December 2010.
Of these, 158 patients with SES and 66 patients with EES
underwent routine 6–12-month follow-up coronary angiography
with OCT examination. Among these, patients who met the
inclusion and exclusion criteria were prospectively enrolled in
this study for sequential angiographic and OCT examinations.
The inclusion criteria for this study were as follows: (a) patients
with a de novo coronary lesion (>50% diameter stenosis) treated
with SES or EES, who underwent routine 6–12-month follow-up
coronary angiography and OCT; (b) native vessel size of 2.5–
3.5 mm in diameter, and (c) stable angina or acute coronary
syndrome. The exclusion criteria were as follows: (1) patients
with ST-elevated acute myocardial infarction, (2) target lesion
revascularization during follow-up, and (3) patients unsuitable
for coronary angiography due to renal dysfunction or congestive
heart failure. Eventually, 8 SES from 7 patients and 31 EES from
23 patients were enrolled in the study. All patients were taking
dual antiplatelet therapy with aspirin 100 mg/day and clopido-
grel 75 mg/day or ticlopidine 200 mg/day, for at least 6 months
after EES implantation.
OCT examination
The OCT examination was performed serially, 6–12 months
after stenting as mid-phase follow-up and 24 months after
stenting as late-phase follow-up. In the present study, because
frequency-domain OCT had not been approved for clinical use in
Japan at the time of the mid-term follow-up, time-domain OCT
with coronary artery occlusion was used for imaging in the mid-
and late-phase follow-up examinations. The OCT examination
was performed as previously reported [9]. Brieﬂy, a 0.016-in.
OCT catheter (Image Wire, LightLab Imaging, Westford, MA, USA)
was advanced to the distal end of the stented lesion. The
occlusion balloon (HeliosTM, LightLab Imaging, Inc.) was inﬂated
to 0.5 atm at the proximal site of the stented lesion; then
lactated Ringer’s solution was infused into the coronary artery
from the distal tip of the occlusion balloon catheter at 0.5–
0.7 mL/s to clear the area of blood. The entire stented length of
the lesion was then imaged using an automatic pullback system
moving at 1 mm/s.
Quantitative coronary angiography analysis
Coronary angiograms, obtained at baseline, the mid-phase (12
months), and the late-phase (24 months) follow-up, were
analyzed using a computer-based system with edge-detection
techniques (QCA-CMS5.1, Medis Imaging Systems, Leiden,
Netherlands). Late loss was deﬁned as the difference between
the minimum lumen diameter (MLD) after the procedure and at
the mid-phase follow-up. Delayed late loss was deﬁned as the
difference between the MLD at the mid-phase and at the late-
phase follow-up.OCT analysis
Off-line OCT analysis was performed using the dedicated
software (LightLab Imaging, Inc.). For quantitative analysis, cross-
sectional OCT images were analyzed at 1-mm intervals. We used
the distance from the stent edge and landmarks such as side
branches to match the location of the cross-sections between the
mid-phase and late-phase examinations. The stent and lumen area
were measured manually, and the neointimal area was calculated
as stent area minus lumen area.
Neointimal thickness was deﬁned as the distance between the
stent strut and the lumen surface. An uncovered strut was deﬁned
as a strut with a neointimal thickness equal to 0 mm. The frequency
of covered and uncovered struts was calculated as the number of
those struts divided by the total number of struts for each stent. A
malapposed strut was deﬁned as a distance of more than 108 mm
in EES and 170 mm in SES between the center reﬂection of the strut
and the vessel wall. EES criterion was determined by adding the
actual strut thickness and polymer thickness to the OCT resolution
limit (81 mm + 7 mm + 20 mm = 108 mm) [10]. The frequencies of
struts with a peri-strut low intensity area (PLIA) and an extra-stent
lumen (ESL) were calculated. PLIA was deﬁned as a region around
stent struts with a homogeneous lower intensity than the
surrounding tissue on OCT images, without signiﬁcant signal
attenuation behind the area [11]. ESL was deﬁned as a lumen
external to the stent struts [6].
The frequency of atherogenic neointima (AN) (indicating
neoatherosclerosis) and intra-stent thrombus was calculated.
AN was deﬁned as neointima containing a diffuse border and a
signal-poor region, with the struts underneath invisible because
of the marked signal attenuation [12,13]. Intra-stent thrombus
was deﬁned as a mass protruding beyond the stent strut into the
lumen, with signiﬁcant attenuation behind the mass [14]. The
presence of PLIA, ESL, and intra-stent thrombus required the
agreement of two independent experienced observers (T.S. and
H.O.). Representative images of cases with AN and thrombus are
shown in Fig. 1.
Statistical analysis
The statistical analysis was conducted using the commercially
available SPSS software version 16.0 (SPSS Inc, Chicago, IL, USA).
Qualitative data are presented as frequencies and quantitative data
as mean values  SD. For continuous variables, comparisons
between two groups were performed using a 2-tailed, unpaired
t-test or the Wilcoxon test. Discrete variables are presented as
percentages and comparisons were performed by chi-square analysis
or Fisher’s exact test. A multivariate logistic regression analysis
was done to ﬁnd out the independent factors for the minimum lumen
area (MLA) change and neointimal thickness (NIT) change. A
probability value (p) of less than 0.05 was considered signiﬁcant.
Results
Baseline patient and lesion characteristics
Baseline patient and lesion characteristics were matched
between the EES group and SES group (Table 1). There was no
statistical difference regarding the percentage of patients under
dual antiplatelet therapy at the mid- and late-phase follow-up
between the groups.
Angiographic analysis
Although in-stent MLD at the mid-phase follow-up showed no
signiﬁcant difference between EES and SES group, in-stent late loss
Fig. 1. Representative optical coherence tomography images. (A) Atherogenic neointima (SES) and (B) intra-stent thrombus (EES). SES, sirolimus-eluting stent; EES,
everolimus-eluting stent.
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(Table 2).
OCT analysis
In both EES and SES groups, the average lumen area and average
MLA decreased from the mid- to the late-phase follow-up due toTable 1
Baseline patient and lesion characteristics.
Variable EES SES p-value
n = 23 n = 7
Age (years) 71.6  8.5 63.6  13.0 0.04
Male (%) 73.9 100 0.15
BMI (kg/m2) 24.3  3.3 25.4  3.2 0.48
Mean follow-up duration (months)
Mid-phase follow-up 10.9  2.8 9.9  2.3 0.37
Late-phase follow-up 23.8  2.3 22.0  2.9 0.13
Risk factors (%)
Diabetes mellitus 52.2 57.1 0.82
Hypertension 82.6 85.7 0.85
Dyslipidemia 78.3 57.1 0.27
Current smoker 26.1 42.9 0.40
Prior MI 21.7 14.3 0.67
Prior PCI 47.8 28.6 0.37
Prior CABG 0.0 0.0 NS
Ejection fraction (%) 57.0  12.7 56.1  11.7 0.78
Angina status (%)
Stable 83.9 100 0.22
Unstable 3.2 0.0 0.61
Acute MI 12.9 0.0 0.28
Lesion characteristics (%)
Vessel treated (LAD/LCX/RCA) 55/26/19 50/25/25 0.19
ACC-AHA class (A-B1/B2-C) 35/65 25/75 0.57
De novo/in-stent restenosis 87/13 100/0 0.28
Antiplatelet therapy at mid-phase follow-up (%)
Aspirin 100 100 NS
Clopidogrel 91.3 85.7 0.67
Ticlopidine 4.3 0.0 0.57
Antiplatelet therapy at late-phase follow-up (%)
Aspirin 100 100 NS
Clopidogrel 82.6 71.4 0.52
Ticlopidine 4.3 14.3 0.36
SES, sirolimus-eluting stent; EES, everolimus-eluting stent; BMI, body mass
index; MI, myocardial infarction; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft; LAD, left anterior descending; LCX, left
circumﬂex; RCA, right coronary artery; ACC-AHA, American College of
Cardiology-American Heart Association.increased neointimal area (Table 3). However, EES showed less
lumen narrowing than SES due to less increase in neointima
proliferation from the mid- to the late-phase follow-up (Table 4).
Detailed strut-based measurement of NIT showed that EES showed
no signiﬁcant changes from the mid- to the late-phase follow-up,
while there was a tendency toward an increased average NIT in SES
treated lesions. The change in NIT from the mid- to the late-phase
follow-up was signiﬁcantly larger in SES than EES (Table 4). The
stepwise multiple logistic regression analysis revealed that only
stent type (EES or SES) was the independent factor for MLA changes
(p = 0.034), and NIT changes (p = 0.022) and other baseline
characteristics were not independently associated with these
changes.
The incidence of uncovered struts of EES was lower than that of
SES, at the time of the mid-phase follow-up and remained lower at
the late-phase follow-up (Table 3).
The percentage of struts with PLIA of EES was lower than that
of SES at both mid-phase follow-up and late-phase follow-up and
decreased signiﬁcantly during the follow-up period while
remaining unchanged in SES. Stents with in-stent thrombus of
EES tended to be lower than that of SES at both phase follow-ups
and decreased signiﬁcantly during the follow-up period, whereasTable 2
Quantitative angiographic analysis (EES, SES).
EES (31 stents) SES (8 stents) p
Pre-intervention
Reference vessel diameter (mm) 2.45  0.46 2.19  0.52 0.18
Minimal lumen diameter (mm) 0.60  0.35 0.89  0.51 0.06
% Diameter stenosis 68.5  16.5 59.8  17.9 0.20
Lesion length (mm) 15.8  6.5 11.3  5.7 0.08
Post-intervention
Minimal lumen diameter (mm) 2.33  0.41 2.33  0.28 0.98
% Diameter stenosis 9.34  6.44 10.0  3.4 0.78
Mid-phase follow-up
Minimal lumen diameter (mm) 2.20  0.40 1.93  0.44 0.11
% Diameter stenosis 13.3  5.60 24.6  13.1 0.0007
Late loss (mm) 0.13  0.27 0.40  0.32 0.02
Late-phase follow-up
Minimal lumen diameter (mm) 2.19  0.42 1.79  0.30 0.02
% Diameter stenosis 12.4  5.41 27.6  12.8 <0.0001
Delayed late loss (mm) 0.003  0.14 0.14  0.26 0.04
Values are presented as mean  SD or percent. SES, sirolimus-eluting stent; EES,
everolimus-eluting stent.
Table 3
Optical coherence tomography analysis.
EES SES
Mid-phase Late-phase p Mid-phase Late-phase p
Stent-based analysis
Stent with 100% covered struts (n, %) 19 (61.3) 22 (71.0) 0.42 3 (37.5) 5 (62.5) 0.32
Stent with ESL (n, %) 7 (22.6) 6 (19.4) 0.76 6 (75.0) 5 (62.5) 0.59
Stent with in-stent thrombus (n, %) 4 (12.9) 0 (0) 0.04 3 (37.5) 2 (25.0) 0.59
Stent with AN (n, %) 0 (0) 0 (0) NS 1 (12.5) 2 (25.0) 0.52
Cross-section-based analysis
Average lumen area (mm2) 5.17  2.17 5.04  2.19 0.01 5.67  1.37 5.38  1.35 0.13
Average minimum lumen area (mm2) 4.00  2.16 3.94  2.15 0.38 3.63  1.43 3.19  1.54 0.13
Average stent area (mm2) 6.09  2.16 6.06  2.18 0.20 6.92  1.68 6.92  1.61 0.91
Average neointimal area (mm2) 0.92  0.46 1.02  0.46 0.01 1.25  0.70 1.54  1.08 0.11
Average % neointimal area (%) 16.3  8.5 18.2  9.1 0.01 17.3  8.3 21.4  13.7 0.10
Strut-based analysis
Average number of struts 182  79 171  62 0.22 178  73 170  72 0.13
Average neointimal thickness (mm) 115.5  66.6 120.7  63.0 0.33 134.4  73.4 171.6  111.8 0.07
Average uncovered struts (%) 0.63  1.01 0.60  1.28 0.80 2.89  3.25 3.42  4.76 0.77
Average malapposed struts (%) 0.27  1.10 0.05  0.17 0.29 0.33  0.56 0.23  0.51 0.74
Average struts with PLIA (%) 6.21  5.85 4.56  4.48 0.01 15.5  11.5 13.6  10.0 0.35
SES, sirolimus-eluting stent; EES, everolimus-eluting stent; PLIA, peri-strut low intensity area; ESL, extra-stent lumen; AN, atherogenic neointima.
Table 4
Delta value of optical coherence tomography analysis.
Variable EES SES p-value
Mid to late phase Mid to late phase
Cross-section-based analysis
Average Dlumen area (mm2) 0.13  0.23 0.29  0.49 0.18
Average Dminimum lumen area (mm2) 0.06  0.36 0.45  0.74 0.04
Average Dneointimal area (mm2) 0.10  0.21 0.29  0.45 0.08
Strut-based analysis
Average Dneointimal thickness (mm) 5.2  29.4 37.2  48.9 0.02
Average Duncovered struts (%) 0.03  1.41 0.53  4.85 0.49
Average Dmalapposed struts (%) 0.22  1.11 0.10  0.83 0.91
SES, sirolimus-eluting stent; EES, everolimus-eluting stent.
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unchanged. The frequencies of ESL of EES were lower than that
of SES at both phase follow-ups (Table 3) and AN was not
observed at either phase in EES, while observed in 1 SES at the
mid-phase follow-up and in 2 SES at the late-phase follow-up.
Representative OCT images of the mid- and the late-phase
follow-up are shown in Fig. 2.
Discussion
In the present study, although both stents showed progressive
luminal narrowing, the extent of delayed lumen narrowing and
delayed neointimal proliferation was signiﬁcantly greater in the
ﬁrst generation SES than the second generation EES. The incidence
of uncovered struts, struts with PLIA, and stents with thrombus, all
of which are considered to represent delayed arterial healing, were
signiﬁcantly higher for SES than EES at both mid- and the late-
phase follow-up, while stents with ESL were more frequently
observed in SES than EES at both phases. In this patient population,
AN was not detected by OCT in any EES case, while observed in 15%
of SES cases at mid-phase and 25% at late-phase follow-up.
Long-term neointimal suppression
Recently, Kuriyama et al. [15], assessing 2008 lesions using
serial quantitative coronary angiography (8 months and 2 years),
identiﬁed a signiﬁcant decrease in MLD (from 2.56 mm to
2.35 mm, p < 0.001) with a late restenosis rate of 7.1% amongpatients treated with SES. In contrast, angiographic and OCT data
for EES are limited beyond 6–9-month follow-up. In a serial
angiographic analysis of the SPIRIT II trial, a signiﬁcant angio-
graphic late loss and neointimal volume increase by intravascular
ultrasound from the 6-month to the 2-year follow-up was
observed in a subset of 152 patients who underwent serial
angiographic and intravascular ultrasound analyses [16]. This is
consistent with our OCT analysis, where there was signiﬁcant
delayed lumen area loss with a signiﬁcant increase of neointima
area from the mid- to the late-phase follow-up. Although both
stents showed progressive luminal narrowing from the mid-phase
to the late-phase follow-up, EES showed a signiﬁcantly less
delayed neointimal proliferation during the follow-up. The
mechanism of the delayed neointimal growth is multifactorial.
Previous animal studies imply that it is partly due to inﬂammation
and delayed cellular proliferation in response to local vessel injury
during stenting. In addition, the drug and polymer used in each DES
might explain such differences. Also, shear stress-mediated
remodeling has been considered to contribute to the late
‘‘catch-up’’ phenomenon [17]. Regions with low shear stress and
the presence of turbulent ﬂow in the treated coronary segment
have been found to be predisposed to neointimal growth [17].
Therefore, besides different drug and polymer used in EES and SES,
differences in stent design and strut thickness could also have led
to different time courses of vessel healing, possibly as a result of
differences in the distribution of shear stress after stent placement.
These factors might explain the somewhat smaller extent of late
catch-up phenomena observed in EES as compared with SES.
Fig. 2. Representative optical coherence tomography images of the temporal change in the mid- and late-phase follow-up. (A) EES: thin neointima is covering the entire stent
struts at the mid-phase and slight increase of neointimal thickness was observed at the late phase follow-up. (B) SES: uncovered struts were observed at the mid-phase
follow-up, and signiﬁcant intimal thickening was observed at the late-phase follow-up. SES, sirolimus-eluting stent; EES, everolimus-eluting stent.
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Previous reports have suggested that delayed arterial healing,
characterized by the presence of exposed stent struts and ﬁbrin or
thrombus deposition with persistent inﬂammatory cell inﬁltration,
has been associated with late stent thrombosis. Therefore, several
OCT ﬁndings, such as uncovered struts, malapposed struts, PLIA,
and intra-stent thrombus, can be considered as surrogate markers
of this phenomenon.
One serial OCT study with 21 SES-treated lesions reported that
the percentage of uncovered struts was 3.2% at 2-year follow-up
[6]. Another 2-year follow-up OCT study showed that the
percentage of uncovered struts was 6.5% in 20 SES-treated lesions
[8,18]. Although previous long-term OCT studies consistently
reported progressive vessel healing long after ﬁrst-generation DESimplantation, the incidence of uncovered struts remained high at 2
years and an almost 30% incidence of thrombus formation was
observed 2 years after stenting [19,20]. These ﬁndings are in
line with the results of SES group of the present study that the
incidence of uncovered struts was 2.89  3.25% in the mid-phase
follow-up and 3.42  4.76% in the late phase follow-up. Also the
incidence of thrombus was 37.5% in the mid-phase follow-up and
25.0% in the late phase follow-up. These data suggest that ﬁrst-
generation DES may still be in a biologically active state, so that the
lesions were not stabilized 2 years after stenting. In contrast, the
incidence of thrombus attachment observed at mid-phase follow-up
of EES in our study was 12.9%, which is relatively low compared to
that of ﬁrst-generation DES [9] and is consistent with previous reports
from our center [10]. In addition, all the thrombus observed at mid-
phase follow-up had resolved and disappeared by 2-year follow-up;
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mid- to the long-term follow-up observed in the present study.
The incidence of uncovered struts and malapposed struts, both
of which have been suggested as risk factors for stent thrombosis,
was already low at the time of mid-phase follow-up in the present
study cohort, probably leading to a relatively lower incidence of
thrombus attachment after EES implantation. In addition, the
incidence of completely covered stents was high at the mid-phase
follow-up and tended to increase gradually (from 61.3% to 71.0%,
p = 0.42), while the incidence of struts with PLIA numerically
decreased from the mid- to the late-phase follow-up, suggesting
further progressive vessel healing continuing up to 2 years after
stenting.
Neoatherosclerotic changes in the neointima
To date, several factors have been suggested as possible risk
factors for late stent thrombosis and delayed target lesion
revascularization: the so-called late DES failure. Among these,
atherogenic changes within neointima have been considered to
play an important role in late DES failure. Nakazawa et al. [3],
evaluating a total of 299 autopsy cases, reported that the incidence
of atherogenic neointima was 29% at <2 years after ﬁrst-
generation DES implantation. Recently, Kang et al. [12] demon-
strated the ability of OCT to detect atherogenic changes within
neointima and reported a relation between the presence of
atherogenic neointima and late DES failure. On the other hand,
there was no case with atherogenic neointima at 12 months as well
as 24 months in the EES group of the present study, while AN was
observed in 12.5% of SES cases at the mid-phase and 25% at the
late-phase follow-up. Although the underlying mechanisms
responsible for the development of AN are likely to be multifacto-
rial, delayed endothelial regrowth or its incomplete functional
recovery has been considered to play an important role in the
development of atherogenic changes within neointima [3]. In this
context, an animal study has shown rapid endothelialization of EES
as compared with ﬁrst-generation DES. Joner et al. [21], by
assessing the paradoxical vasoconstriction following acetylcholine
administration, revealed that the endothelial function of EES-
treated lesions was more preserved than that of lesions receiving
SES. Therefore, we speculate that relatively rapid and more
functionally complete endothelialization within EES might protect
against neoatherogenic progression in lesions treated with EES.
Study limitations
First, this was a single-center study with a relatively small
sample size, owing to the invasive nature of the evaluation, raising
the possibility of selection bias. Second, the populations of the EES
and SES groups were heterogeneous, and because the EES group
included acute coronary syndrome patients, that might obscure
the interpretation of results. A previous study, however, showed
that EES had similar neointima thickness and incidence of
uncovered struts for patients with acute myocardial infarction
and stable angina [22]. Also, we have performed all the OCT
comparisons between EES and SES by excluding 5 acute coronary
syndrome lesions (4 acute myocardial infarction and 1 unstable
angina pectoris) and found that the major results were similar to
those of the overall population primarily enrolled in the original
version of the manuscript. Therefore, the results from the current
study offer valid information, although a clinical study including a
homogeneous study population will be necessary to further
conﬁrm our study results. Moreover, there might be some
differences in baseline patient and lesion backgrounds between
SES and EES, which did not become obvious due to limited sample
size. However, stepwise multiple logistic regression analysisrevealed that stent type (EES or SES) was the only independent
factor for MLA changes and NIT changes. Third, the proportion of
the complex lesion (type B2, C of American Heart Association-
American College of Cardiology classiﬁcation) appeared to be
higher than other previous trials, which might cause relatively
large late loss in SES when compared with previous trials. Fourth,
lumen measurements by time-domain OCT can be slightly
different from those by frequency-domain OCT because of the
effect of proximal balloon occlusion. However, a previous report
indicated that stented segments may be less affected or not
affected by proximal occlusion because stent has a considerable
radial strength and allows the vessel dimensions to be maintained
[23]. Therefore, we currently consider that the lumen and stent
dimensions at stented segments by time-domain OCT could be
applicable to the current era of optical frequency domain imaging
or frequency domain OCT, although time-domain OCT is no longer
used in current clinical setting. Fifth, because we did not perform
intravascular imaging before percutaneous coronary intervention
for all the cases, we could not evaluate differences in lesion
characteristics between EES- or SES-treated lesions. Also, although
we compared the incidence of malapposed struts between the two
stent groups, we could not clarify whether these are persistent or
acquired late due to the lack of OCT images immediately after
stenting. Sixth, the time interval from stent implantation to mid-
phase follow-up was wide. That might inﬂuence the results of OCT
examination, although mean duration of follow-up of both groups
was not statistically different.
Finally, the clinical relevance of our ﬁndings is unclear, as is the
question of whether the late neointimal catch-up observed in the
EES treatment group translates into an increased revascularization
rate. These limitations warrant a further study involving a larger
population with a longer follow-up period.
Conclusion
Although both SES and EES showed progressive luminal
narrowing from the mid- to the late-phase follow-up, the extent
of the delayed lumen narrowing and delayed neointimal prolifer-
ation was signiﬁcantly less in the second-generation EES than the
ﬁrst-generation SES. Considering that improved neointimal
coverage without an excess of neointimal proliferation was
observed between the mid- and the late-phase follow-up after
EES implantation, EESs appear to offer sustained stability in
efﬁcacy, without sacriﬁcing safety, up to 2 years after implantation.
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